Access Solutions

Reimbursement Support

To speak live with one of our Specialists, call (866) 681-3261 from 6 a.m.–5 p.m. PT, Monday to Friday, fax (866) 681-3288 or visit RituxanAccessSolutions.com

Copyright Print Page

Genentech, Inc and Biogen Idec, Inc. hereby authorize you to copy documents or pages published by Genentech, Inc and Biogen Idec, Inc. on this website for your non-commercial use only, provided any copy of these documents that you make retains all copyright or other proprietary notices and any disclaimer contained thereon. This publication is provided "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF IMPLIED WARRANTIES, SO THAT ABOVE EXCLUSION MAY NOT APPLY TO YOU.

Indication

Rituxan® (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is not recommended for treatment of patients with severe active infections.

Important Safety Information

  • Rituxan has been associated with fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy (PML)
  • Hepatitis B reactivation, cardiac arrhythmias, and angina have also been observed
  • Patients should be closely observed for signs of infection if biologic agents and/or DMARDs other than methotrexate are used concomitantly
  • Common adverse reactions include infusion reactions and infections

Please see full prescribing information, including Boxed Warnings for additional safety information.